JCG
CHRS icon

JHL Capital Group’s Coherus Oncology CHRS Stock Holding History

JHL Capital Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-700,000
Closed -$14.8M – 18
2017
Q1 		$14.8M Buy
700,000
+450,000
+180% +$11.1M 3.19% 10
2016
Q4 		$7.04M Buy
+250,000
New +$7M 0.55% 13

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JHL Capital Group's CHRS Position: Q2 2017 in Review

JHL Capital Group sold out of Coherus Oncology (CHRS) in Q2 2017, closing a stake of 700,000 shares — an estimated $14.8M sold.

JHL Capital Group first reported a position in CHRS in Q4 2016 and held it in 2 quarters. The position peaked at $14.8M in Q1 2017. 106 funds tracked by Wall St. Rank hold CHRS as of Q2 2017.

  • JHL Capital Group reported no remaining Coherus Oncology position as of Q2 2017 after selling out during the quarter.
  • JHL Capital Group sold 700,000 Coherus Oncology shares in Q2 2017, an estimated $14.8M.
  • JHL Capital Group first reported a position in Coherus Oncology in Q4 2016 and held it in 2 quarters.
  • JHL Capital Group's Coherus Oncology position peaked at $14.8M in Q1 2017.
  • 106 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2017.

Based on JHL Capital Group's 13F filing for Q2 2017, filed 14 Aug 2017.